Next-Gen ADCs: Araris CEO Highlights Potential In Linker Technology

 
• By Janelle Hart

In Vivo sat down with 2023 Rising Leader Philipp Spycher, CEO of Araris Biotech, to discuss trends in antibody-drug conjugate R&D, and how Araris hopes to disrupt today’s chemotherapy treatment paradigm with novel linker technology.

Antibody-drug conjugates
• Source: Shutterstock

More from Rising Leaders

More from Leadership